GC Cell advances NK therapy toward potential first Korean commercialization
AI Summary- GC Cell is accelerating development of next-generation NK cell therapies.
- Artiva plans a Phase 3 trial enrolling about 150 patients for GCC4001.
- GC Cell formed in 2021 through the merger of GC LabCell and GC Cell Therapy.